John Glenn - 20 Jun 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: IRMD
Reported as of: 20 Jun 2025
Net transaction value: -$82,235
SEC form: 4
Accepted by SEC: 23 Jun 2025, 20:00:21 UTC
Prior SEC filing: 13 Dec 2024
Next SEC filing: 12 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ John Glenn

Key filing fact

John Glenn filed Form 4 for IRADIMED CORP (IRMD) on 23 Jun 2025.

Key facts

This page summarizes John Glenn's Form 4 filing for IRADIMED CORP (IRMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2025, 20:00.

Change

Previous filing in this sequence was filed on 13 Dec 2024.
Current net transaction value: -$82,235.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253497 Primary reporting owner

GLENN JOHN

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS
Signature: /s/ John Glenn
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,796
Change %: +66%
Price
Shares after: 14,563
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F1

IRMD transaction

Common Stock

Tax liability

Transaction value: $82,235
Shares: -1,412
Change %: -9.7%
Price: $58.24
Shares after: 13,151
Date: 20 Jun 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -5,796
Change %: -50%
Price: $0.000000
Shares after: 5,796
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,796
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

Footnote F2

On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.